肺癌靶向治疗分子检测指南更新(CAP/IASLC/AMP)
重申细胞学样本可检测、提高检测灵敏度、反对用免疫组化检测EGFR,新增ROS1检测及更多可检测基因等推荐。
要点
- 所有腺癌患者应检测ROS1;NGS panel实验室可纳入ERBB2、MET、BRAF、KRAS、RET。
- ALK与ROS1检测可用免疫组化替代FISH;EGFR T790M检测采用5%灵敏度方法。
- 组织有限或难获取时可用游离DNA「纳入」可靶向突变。
核心结论
- 2013年指南总体被重申,并通过更新推荐扩大检测范围、允许细胞学样本、提高检测灵敏度,并明确反对用免疫组化检测EGFR。
研究设计与样本
- 由美国病理学家学会、国际肺癌研究学会与美国分子病理学协会召集专家组制定循证指南,确定关键问题与文献检索词,审阅摘要与全文后起草推荐。
主要发现
- 新增推荐包括:所有腺癌患者检测ROS1;开展下一代测序panel的实验室纳入ERBB2、MET、BRAF、KRAS和RET。
- ALK和/或ROS1检测可用免疫组化替代荧光原位杂交;对EGFR抑制剂继发耐药患者,EGFR T790M突变采用5%灵敏度检测方法。
- 组织有限或难以获取时,可用游离DNA「纳入」可靶向突变。
关键数值与推荐
- 所有腺癌患者:推荐ROS1检测。
- 下一代测序panel实验室:纳入ERBB2、MET、BRAF、KRAS、RET。
- ALK和/或ROS1:免疫组化可作为荧光原位杂交的替代方法。
- EGFR抑制剂继发耐药患者:EGFR T790M突变采用5%灵敏度检测方法。
- 组织有限或难获取:可用游离DNA「纳入」可靶向突变。
临床怎么用
- 肺腺癌患者应常规评估ROS1;开展NGS panel的实验室应覆盖ERBB2、MET、BRAF、KRAS、RET等基因。
- ALK/ROS1检测可优先或联合使用免疫组化;EGFR T790M耐药检测应选用5%灵敏度方法。
- 组织标本不足或难以获取时,可考虑用游离DNA检测可靶向突变以「纳入」治疗相关变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In 2013, an evidence-based guideline was published by the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology to set standards for the molecular analysis of lung cancers to guide treatment decisions with targeted inhibitors. New evidence has prompted an evaluation of additional laboratory technologies, targetable genes, patient populations, and tumor types for testing. OBJECTIVE: To systematically review and update the 2013 guideline to affirm its validity; to assess the evidence of new genetic discoveries, technologies, and therapies; and to issue an evidence-based update. DESIGN: The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology convened an expert panel to develop an evidence-based guideline to help define the key questions and literature search terms, review abstracts and full articles, and draft recommendations. RESULTS: Eighteen new recommendations were drafted. The panel also updated 3 recommendations from the 2013 guideline. CONCLUSIONS: The 2013 guideline was largely reaffirmed with updated recommendations to allow testing of cytology samples, require improved assay sensitivity, and recommend against the use of immunohistochemistry for EGFR testing. Key new recommendations include ROS1 testing for all adenocarcinoma patients; the inclusion of additional genes (ERBB2, MET, BRAF, KRAS, and RET) for laboratories that perform next-generation sequencing panels; immunohistochemistry as an alternative to fluorescence in situ hybridization for ALK and/or ROS1 testing; use of 5% sensitivity assays for EGFR T790M mutations in patients with secondary resistance to EGFR inhibitors; and the use of cell-free DNA to "rule in" targetable mutations when tissue is limited or hard to obtain.
引用
- Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018. PMID: 29396253. doi:10.1016/j.jtho.2017.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。